Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
IMNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.64 - $3.65
Previous CloseN/A
Volume151.93K
Average Volume (3M)141.97K
Market Cap
$16.67M
Enterprise Value$9.04M
Total Cash (Recent Filing)$2.35M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 19, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding14,620,732
10 Day Avg. Volume142,352
30 Day Avg. Volume141,967
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$14.00Price Target Upside1184.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Imunon News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsImproved overall survival hazard ratio and increased survival benefit have been shown with IMNN-001 treatment.
Cost ManagementImunon's cost-effective approach, including in-house manufacturing and competitive pricing, has allowed it to beat internal cost projections for the trial.
Regulatory ApprovalImunon has full FDA alignment for its OVATION 3 trial, which is a positive development for advancing their study.
Bears Say
Funding ChallengesThe company has sufficient funding to initiate the Phase 3 program though will need to raise additional capital in 2025.
Market CompetitionThe trial is set to enroll approximately 500 women with ovarian cancer and will be a broad trial including both BRCA+/HRD and BRCA-/HRP patients, indicating potential competition with other treatments targeting similar populations.
---
Ownership Overview
4.88% Insiders
1.20% Mutual Funds
<0.01% Other Institutional Investors
93.58% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $0.64 and its highest was $3.65 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $16.67M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is May 19, 2025 which is in 50 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Feb 27, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.108.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.35.
How many shares outstanding does Imunon have?
Imunon has 14,620,732 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went up 1.25%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
---
Company Description
Imunon
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
---
IMNN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and potential for accelerated approval of Imunon-001, alongside strong safety data. However, concerns about cash runway and funding needs were also discussed, indicating a need for careful financial management.Read More>---
IMNN Stock 12 Month Forecast
Average Price Target
$14.00
▲(1184.40% Upside)
Technical Analysis
Best Analysts Covering IMNN
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-16.96%
reiterated a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -16.96% per trade.
---